Patents Assigned to iNtRON Biotechnology, Inc.
  • Patent number: 10696989
    Abstract: The present invention relates to heme iron not derived from porcine blood and a method of preparing the same, and more particularly to a method of biologically preparing heme iron not derived from porcine blood, a method of preparing a salt thereof, and an iron supplement containing the salt thus prepared as an active ingredient.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: June 30, 2020
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Jung In Pyo, Soon Hye Hwang, Soo Youn Jun, Sang Hyeon Kang
  • Patent number: 10618934
    Abstract: Provided are a novel peptide compound, a method of producing the same, and use of the peptide compound. Since the peptide compound has anticancer activity, the peptide compound may be used for the prevention or treatment of cancer.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: April 14, 2020
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Jong Heon Shin, Ki Bong Oh, Dong Chan Oh, Sang Kook Lee, Lijuan Liao, Min Jung You
  • Patent number: 10568917
    Abstract: The present invention relates to: Myoviridae bacteriophage Pas-MUP-1 (accession number KCTC 12706BP) which has the capability to specifically destroy Pasteurella multocida, is characterized by having a genome represented by SEQ ID NO: 1, and is isolated from nature; and a method for preventing and treating Pasteurella multocida infections, using a composition containing bacteriophage Pas-MUP-1 as an active ingredient.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 25, 2020
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Dong Min Kang, Sang Hyeon Kang
  • Patent number: 10337044
    Abstract: Vectors expressing kanA-kanB-kanK and other kanamycin production-related genes, Streptomyces species recombinant bacteria transformed with the vectors, a method of producing kanamycin antibiotics by the bacteria, and a new kanamycin compound produced by the bacterium are provided. With the use of the recombinant bacteria of the present invention, the direct fermentative biosynthesis of amikacin and tobramycin as semi-synthetic kanamycins is possible, and the yield of kanamycin B as a precursor of the semi-synthetic kanamycin is improved.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: July 2, 2019
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Yeo Joon Yoon, Sung Ryeol Park, Je Won Park, Jae Kyung Sohng
  • Publication number: 20190183803
    Abstract: A freeze-dried formulation includes an antibacterial protein having killing activity specific to at least one of or all following species: Staphylococcus arlettae, Staphylococcus aureus, Staphylococcus auricularis, Staphylococcus carnosus, Staphylococcus carprae, Staphylococcus chromogenes, Staphylococcus cohnii, Staphylococcus delphini, Staphylococcus epidermidis, Staphylococcus equorum, Staphylococcus gallinarum, Staphylococcus hemolyticus, Staphylococcus hominis, Staphylococcus intermedius, Staphylococcus kloosii, Staphylococcus lentus, Staphylococcus lugdunensis, Staphylococcus muscae, Staphylococcus pasteuri, Staphylococcus saprophyticus, Staphylococcus warneri, and Staphylococcus xylosus; a poloxamer; a sugar, and an amino acid.
    Type: Application
    Filed: January 9, 2017
    Publication date: June 20, 2019
    Applicant: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun YOON, Soo Youn JUN, Gi Mo JUNG, Sang Hyeon KANG
  • Patent number: 10265356
    Abstract: The present invention relates to a Myoviridae bacteriophage Esc-COP-4 that is isolated from the nature and can kill specifically enteroinvasive E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12663BP), and a method for preventing and treating the infections of enteroinvasive E. coli using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 23, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Byung Kuk Kim, Hee Jeong Shin, Dong Min Kang
  • Patent number: 10265353
    Abstract: The present invention relates to a Myoviridae bacteriophage Esc-CHP-1 that is isolated from the nature and can kill specifically enterohemorrhagic E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12660BP), and a method for preventing and treating the infections of enterohemorrhagic E. coli using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 23, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Byung Kuk Kim, Hee Jeong Shin
  • Patent number: 10265355
    Abstract: The present invention relates to a Myoviridae bacteriophage Esc-COP-1 that is isolated from the nature and can kill specifically Shigatoxin-producing type F18 E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12662BP), and a method for preventing and treating the infections of Shigatoxin-producing type F18 E. coli using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 23, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Suk Hwang Park, Byung Kuk Kim
  • Patent number: 10265354
    Abstract: The present invention relates to a Myoviridae bacteriophage Esc-CHP-2 that is isolated from the nature and can kill specifically enteropathogenic E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12661BP), and a method for preventing and treating the infections of enteropathogenic E. coli using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 23, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Byung Kuk Kim, Hee Jeong Shin
  • Patent number: 10227570
    Abstract: The present invention relates to a Siphoviridae bacteriophage Lac-BRP-1 that is isolated from the nature and can kill Lactobacillus brevis cells specifically, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12659BP), and a method for preventing and treating the contaminations of Lactobacillus brevis by using the composition comprising the bacteriophage as an active ingredient.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: March 12, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Byung Kuk Kim
  • Patent number: 10227571
    Abstract: The present invention relates to a Siphoviridae bacteriophage Lac-PLP-1 that is isolated from the nature and can kill Lactobacillus plantarum cells specifically, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12665BP), and a method for preventing and treating the contaminations of Lactobacillus plantarum by using the composition comprising the bacteriophage as an active ingredient.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: March 12, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Hee Jeong Shin
  • Patent number: 10226060
    Abstract: The present invention relates to a Myoviridae bacteriophage Lac-GAP-1 that is isolated from the nature and can kill specifically Lactococcus garvieae cells, which has a genome represented by the nucleotide sequence of SEQ ID NO: 1 (Accession NO: KCTC 12686BP), and a method for preventing and treating the infections of Lactococcus garvieae using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: March 12, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, An Sung Kwon, Soon Hye Hwang
  • Patent number: 10077468
    Abstract: The present invention relates to a PCR primer facilitating hot-start PCR by suppressing non-specific amplification at room temperature and at the same time capable of reducing significantly non-specific amplification by dominating the amplification of the PCR product rather than the amplification of the original template from the third PCR cycle, more precisely a PCR primer prepared by additionally inserting the reverse-complementary sequence to a certain region starting from the 5?-start site of the 5?-terminus of the original primer which is composed of priming sequence to anneal to a PCR template into the 5?-terminus of the original primer and a PCR method using the same.
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: September 18, 2018
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seongjun Yoon, Hyunyoung Lee, Jinseok Yu, Sooyoun Jun, Sanghyeon Kang
  • Patent number: 10028984
    Abstract: The present invention relates to a Myoviridae bacteriophage Clo-PEP-1 that is isolated from the nature and can kill Clostridium perfringens cells specifically, which has the genome represented by nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12664BP), and a method for preventing and treating the infections of Clostridium perfringens cells using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: July 24, 2018
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Jee Soo Son, Hyoun Rok Paik, Suk Hwang Park
  • Patent number: 9603909
    Abstract: The present invention relates to a composition for improving the stability of bacteriophage originated lysin proteins greatly even when the composition contains the bacteriophage originated lysin proteins at a high concentration. More precisely, the present invention relates to a method and a composition for improving significantly the stability of SAL-1 or LysK, the bacteriophage originated lysin protein, included at a high concentration in the composition.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: March 28, 2017
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Gi Mo Jung, Sang Hyeon Kang
  • Patent number: 9540616
    Abstract: The present invention relates to a composition comprising bacteriophage SP-1, the bacteriophage capable of destroying Salmonella once being infected in Salmonella, as an active ingredient, and a method for prevention and treatment of Salmonella infection using the same. Bacteriophage SP-1, the active ingredient of the composition of the present invention, characteristically has the killing activity to Salmonella and has the genome represented by SEQ. ID. NO: 1.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: January 10, 2017
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sooyoun Jun, Hyoungrok Paik, Gimo Jung, Yoonsik Shin, Sanghyeon Kang
  • Patent number: 9539294
    Abstract: A composition includes an isolated bacteriophage Str-PAP-1 having the ability to kill Streptococcus parauberis cells specifically by infecting the same, and may be used to prevent and treat Streptococcus parauberis infections. The bacteriophage Str-PAP-1 that is an active ingredient of the composition has the ability to kill Streptococcus parauberis cells and characteristically has the genome represented by nucleotide sequence of SEQ. ID. NO: 1.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: January 10, 2017
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, An Sung Kwon, Young Jae Hur, Jung Mi Kim, Sang Hyeon Kang
  • Patent number: 9505779
    Abstract: The present invention relates to novel tacrolimus analogs, a composition for the prevention or treatment of neurological diseases or immune hypersensitivity disorders comprising the same, a method for preventing or treating neurological diseases or immune hypersensitivity disorders comprising administering the analogs to a subject, a method for preparing the analogs using an isolated modified Streptomyces sp. strain wherein the activity of one or more enzymes selected from the group consisting of TcsA, TcsB, TcsC and TcsD is reduced; and the isolated modified Streptomyces sp. strain for prepare the analogs.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: November 29, 2016
    Assignee: Intron Biotechnology, Inc.
    Inventors: Yeo Joon Yoon, Jae Jong Kim, Si Kyu Lim
  • Patent number: 9433653
    Abstract: The present invention relates to a composition comprising the bacteriophage EK88P-1 isolated from the nature and having a broad antibacterial spectrum against E. coli as an active ingredient, and a method for preventing and treating E. coli infections using the said composition. The bacteriophage EK88P-1, the active ingredient of the composition of the present invention, has a broad antibacterial spectrum against E. coli and has the genome characteristically composed of the partial nucleotide sequences represented by SEQ ID NO: 1 to SEQ ID NO: 25, and also characterized by the bacteriophage belonging to the Myoviridae family according to the morphology that is composed of the major structural proteins in the sizes of approximately 49 kDa, 53 kDa, 94 kDa, and 103 kDa.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: September 6, 2016
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoung Rok Paik, Jee Soo Son, Hye In Jeong, Sang Hyeon Kang
  • Patent number: 9402873
    Abstract: The present invention relates to a composition comprising STP-1, a bacteriophage isolated from nature, capable of infecting Salmonella Typhimurium so as to kill the same as an active ingredient, and a method for preventing and treating Salmonella Typhimurium infection using the said composition. According to the present invention, the bacteriophage STP-1, an active ingredient of the composition, has a killing activity against Salmonella Typhimurium and has the genome represented by SEQ. ID. NO: 1.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: August 2, 2016
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Dong Hwan Kim, Sang Hyeon Kang